NanoRibo (Shanghai) Biotechnology Co., Ltd.

NanoRibo, founded in May 2021, is a biopharmaceutical technology company specializing in mRNA-related research and development of innovative vaccines and drugs. Our founding team, with over 20 years of expertise in virology and vaccine research, has played pivotal roles in esteemed research institutions and multinational corporations (MNCs) worldwide with extensive involvement in mRNA research and development, granting us genuine mastery of the technical know-how in the mRNA field.

NanoRibo boasts a solid foundation in pathogenic biology, immunology, molecular biology, and bioinformatics. We are dedicated to fostering original innovation and have created a cutting-edge platform for researching and developing mRNA vaccines and drugs. Our mission at NanoRibo is to pioneer the biopharmaceutical industry, excelling in innovation and thriving in the global market.

We possess proprietary non-coding region sequences, codon optimization algorithms, antigen design and optimization methods based on AI/Deep Learning, circRNA purification processes, LNP lyophilization techniques, and other innovative solutions to industry challenges.

Utilizing the advantages of our mRNA technology platform, we focus on addressing the pressing need for enhancing existing technologies or filling gaps in the market for vaccines and other immunotherapies.

Our major investor

Shanghai Healthcare Capital (SHC), which is approved by the Shanghai Municipal Government and initiated by Shanghai Industrial Investment Holdings, is tasked with managing a total of 50 billion RMB for city-level industrial funds. Leveraging Shanghai's extensive advantages in biopharmaceutical development and industrial resources, the fund aims to create an innovative investment platform within the biopharmaceutical sector. This platform will be anchored in Shanghai and Hong Kong, strategically linked with the Yangtze River Delta, and geared towards global markets.

Ennovation Capital founded in 2015, Ennovation Ventures strategically invests in revolutionary new technologies and new products in the global biopharmaceutical and medical health industry chain, and is committed to becoming a professional investment in the field of biomedicine and medical health mechanism. The company's management team and investors have rich investment experience and industrial background resources in the fields of biomedicine and medical health, and focus on the business value brought by the combination of "life", "health" and "innovation".

SiteMapDisclaimerLinksJoin Us
Copyright © 2021 NanoRibo (Shanghai) Biotechnology Co., Ltd All Rights Reserved. Designed 沪ICP备2022003017号-1
Wanhu

沪公网安备 31011202014165号